Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
942 days ago by
Runtime: 3m17s | Views: 7 |
Not yet rated